Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 3
2010 4
2011 3
2012 2
2014 1
2015 2
2016 2
2017 2
2018 5
2019 3
2020 5
2021 8
2022 1
2023 4
2024 8
2025 10
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity.
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Narikawa Y, et al. Among authors: ariizumi h. Cancer Immunol Immunother. 2025 Aug 19;74(9):289. doi: 10.1007/s00262-025-04111-2. Cancer Immunol Immunother. 2025. PMID: 40828195 Free PMC article.
MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cells.
Toyoda H, Kuramasu A, Hosonuma M, Murayama M, Narikawa Y, Isobe J, Baba Y, Tajima K, Funayama E, Shida M, Maruyama Y, Sasaki A, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Kobayashi S, Horiike A, Hida N, Sambe T, Nobe K, Wada S, Kobayashi H, Tsuji M, Kobayashi S, Tsunoda T, Kudo Y, Kiuchi Y, Yoshimura K. Toyoda H, et al. Among authors: ariizumi h. Sci Rep. 2024 Oct 8;14(1):23401. doi: 10.1038/s41598-024-73712-1. Sci Rep. 2024. PMID: 39379424 Free PMC article.
Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.
Shimizu T, Ohkuma R, Homma M, Nakayama S, Sasaki Y, Muto S, Ieguchi K, Watanabe M, Taguchi A, Takayanagi D, Wada Y, Horiike A, Kubota Y, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Mura E, Yoshimura K, Tsuji M, Kiuchi Y, Suzuki H, Yamochi T. Shimizu T, et al. Among authors: ariizumi h. Front Immunol. 2025 Sep 8;16:1528594. doi: 10.3389/fimmu.2025.1528594. eCollection 2025. Front Immunol. 2025. PMID: 40990022 Free PMC article.
Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.
Watanabe M, Ieguchi K, Onishi N, Shimizu T, Ohkuma R, Suzuki R, Mura E, Iriguchi N, Ishiguro T, Hirasawa Y, Ikeda G, Shimokawa M, Ariizumi H, Horiike A, Yoshimura K, Tsunoda T, Tsuji M, Kobayashi S, Kiuchi Y, Wada S. Watanabe M, et al. Among authors: ariizumi h. Front Oncol. 2025 Jul 14;15:1614102. doi: 10.3389/fonc.2025.1614102. eCollection 2025. Front Oncol. 2025. PMID: 40727473 Free PMC article.
Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.
Watanabe M, Ieguchi K, Shimizu T, Ohkuma R, Suzuki R, Mura E, Iriguchi N, Ishiguro T, Hirasawa Y, Ikeda G, Shimokawa M, Ariizumi H, Yoshimura K, Horiike A, Tsunoda T, Tsuji M, Kobayashi S, Oguchi T, Kiuchi Y, Wada S. Watanabe M, et al. Among authors: ariizumi h. Cancers (Basel). 2025 Jul 18;17(14):2384. doi: 10.3390/cancers17142384. Cancers (Basel). 2025. PMID: 40723266 Free PMC article.
Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors.
Hirasawa Y, Isobe J, Hosonuma M, Tsurui T, Baba Y, Funayama E, Tajima K, Murayama M, Narikawa Y, Toyoda H, Shida M, Sasaki A, Maruyama Y, Amari Y, Mura E, Suzuki R, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Sambe T, Uchida N, Wada S, Kobayashi S, Kiuchi Y, Kuramasu A, Yoshimura K, Tsunoda T. Hirasawa Y, et al. Among authors: ariizumi h. Front Immunol. 2025 May 22;16:1528521. doi: 10.3389/fimmu.2025.1528521. eCollection 2025. Front Immunol. 2025. PMID: 40475781 Free PMC article.
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, Narikawa Y, Toyoda H, Isobe J, Funayama E, Tajima K, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Hamada K, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kobayashi S, Shimane T, Tsunoda T, Kobayashi H, Kiuchi Y, Yoshimura K. Murayama M, et al. Among authors: ariizumi h. Sci Rep. 2024 May 17;14(1):11325. doi: 10.1038/s41598-024-59677-1. Sci Rep. 2024. PMID: 38760458 Free PMC article.
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: ariizumi h. Oncol Lett. 2023 Jul 20;26(3):381. doi: 10.3892/ol.2023.13967. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559573 Free PMC article.
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.
Hamada K, Isobe J, Hattori K, Hosonuma M, Baba Y, Murayama M, Narikawa Y, Toyoda H, Funayama E, Tajima K, Shida M, Hirasawa Y, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Kuramasu A, Horiike A, Kim YG, Tsunoda T, Yoshimura K. Hamada K, et al. Among authors: ariizumi h. Front Immunol. 2023 May 3;14:1164724. doi: 10.3389/fimmu.2023.1164724. eCollection 2023. Front Immunol. 2023. PMID: 37207204 Free PMC article.
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, Baba Y, Isobe J, Funayama E, Tajima K, Shida M, Hamada K, Tsurui T, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Horiike A, Sambe T, Tsuji M, Wada S, Kiuchi Y, Kobayashi S, Tsunoda T, Yoshimura K. Hosonuma M, et al. Among authors: ariizumi h. Cancer Sci. 2024 Mar;115(3):752-762. doi: 10.1111/cas.16061. Epub 2024 Jan 22. Cancer Sci. 2024. PMID: 38254257 Free PMC article.
61 results